Intervention

Standard-of-Care

ClinicalTrials.gov intervention label

Clinical trials5

Recruiting2

Common conditions7

Lead sponsors shown5

Clinical trials

5 shown

ENAVOgliflozin Outcome Trial in Patients With Severe Aortic Stenosis After Transcatheter Aortic Valve ReplacementNCT05672836 · 2024-12-18

NeoAdjuvant Therapy With Trastuzumab-deruxtecan Versus Chemotherapy+Trastuzumab+Pertuzumab in HER2+ Early Breast CancerNCT05704829 · 2024-02-05

Precision Medicine Approach for Early Dementia & Mild Cognitive ImpairmentNCT05894954 · 2023-07-31

Study of Safety, Tolerability, and Pharmacokinetics of Topical Selinexor (KPT-330) Diabetic Foot Ulcer (DFU) PatientsNCT02367690 · 2015-01-01

Loss of Control Eating Following Weight Loss SurgeryNCT02259322 · 2014-09-01

Common conditions

Aortic Valve Stenosis1 Dementia, Mild1 Diabetic Foot Ulcers1 Heart Failure1 HER2-positive Early Breast Cancer1 Loss of Control Eating1 Mild Cognitive Impairment1

Leading sponsors

Alzheimer's Prevention and Reversal Project, Inc.1 Duk-Woo Park, MD1 Karyopharm Therapeutics Inc1 Women's Cancer Study Group GmbH1 Yale University1

Trial status mix

COMPLETED2

RECRUITING2

WITHDRAWN1

Phase mix

PHASE22

NA1

PHASE11

PHASE31

PHASE41

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.